Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 14/20 | 1.00 |
| ▸ | NAALAD2 | Q9Y3Q0 | 5/20 | 0.72 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15739333 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL2450656 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL2450650 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL15739351 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL4669761 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL15739372 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL19352015 | 0.98 | FOLH1 (0.97) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL17573317 | 0.95 | FOLH1 (0.90) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL23839908 | 0.93 | FOLH1 (0.87) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL12572609 | 0.91 | FOLH1 (0.83) | FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000959-A1 | CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION | CORNELL UNIVERSITY | 2024-01-04 | — | — | US | claimed |
| CN-111432844-B | PSMA-targeting amanitine conjugates | 海德堡医药研究有限责任公司 | 2023-10-27 | — | — | CN | claimed |
| EP-3684416-B1 | PSMA-TARGETING AMANITIN CONJUGATES | HEIDELBERG PHARMA RES GMBH (DE) | 2023-03-15 | — | — | EP | claimed |
| US-11583569-B2 | PSMA-targeting amanitin conjugates | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-02-21 | — | — | US | claimed |
| US-20200345807-A1 | PSMA-TARGETING AMANITIN CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2020-11-05 | — | — | US | claimed |
| EP-3684416-A1 | PSMA-TARGETING AMANITIN CONJUGATES | Heidelberg Pharma Research GmbH (DE) | 2020-07-29 | — | — | EP | claimed |
| CN-111432844-A | Amanitine conjugates targeting PSMA | 海德堡医药研究有限责任公司 | 2020-07-17 | — | — | CN | claimed |
| WO-2019057964-A1 | PSMA-TARGETING AMANITIN CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2019-03-28 | — | — | WO | claimed |
| US-12534429-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250388523-A1 | 18F-LABELED PEPTIDE LIGANDS USEFUL IN PET AND CERENKOV LUMINESCENE IMAGING | CORNELL UNIVERSITY (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4648799-A1 | LIGAND-DRUG CONJUGATES | Sun Pharma Advanced Research Company Ltd (IN) | 2025-11-19 | — | — | EP | disclosed |
| US-20250332296-A1 | ZWITTERIONIC METAL CHELATORS | CURADEL SURGICAL INNOVATIONS, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250325712-A1 | TARGETING LIGANDS FOR DISEASE-TARGETED IMAGING AGENTS AND METHODS OF USE THEREFOR | CURADEL SURGICAL INNOVATIONS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250177578-A1 | PSMA-BINDING AGENTS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2025-06-05 | — | — | US | disclosed |
| US-20090061010-A1 | CANCER CELL TARGETING USING NANOPARTICLES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090061010-A1 | CANCER CELL TARGETING USING NANOPARTICLES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2008121949-A1 | CANCER CELL TARGETING USING NANOPARTICLES | BIND BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008058192-A2 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008058192-A2 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388523-A1 | 18F-LABELED PEPTIDE LIGANDS USEFUL IN PET AND CERENKOV LUMINESCENE IMAGING | SCTR, SSTR3, SSTR1 | FOLH1 849/4885NAALAD2 2113/4885RIMKLA 3861/4885 |
| US-12534429-B2 | Heterodimers of glutamic acid | FOLH1, GLUL, SLC25A13 | FOLH1 1/4885NAALAD2 15/4885RIMKLA 23/4885 |
| US-20200345807-A1 | PSMA-TARGETING AMANITIN CONJUGATES | FOLH1, ANPEP, PSMA6 | FOLH1 1/4885NAALAD2 157/4885RIMKLA 995/4885 |
| US-20250325712-A1 | TARGETING LIGANDS FOR DISEASE-TARGETED IMAGING AGENTS AND METHODS OF USE THEREFOR | LGALS1, LGALS8, CD74 | FOLH1 20/4885NAALAD2 956/4885RIMKLA 2948/4885 |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885NAALAD2 7/4885RIMKLA 6/4885 |
| US-20090061010-A1 | CANCER CELL TARGETING USING NANOPARTICLES | CD47, EPCAM, CD44 | FOLH1 279/4885NAALAD2 1525/4885RIMKLA 3697/4885 |
| US-20250177578-A1 | PSMA-BINDING AGENTS AND USES THEREOF | KLK3, FOLH1, DNPEP | FOLH1 2/4885NAALAD2 44/4885RIMKLA 485/4885 |
| US-11583569-B2 | PSMA-targeting amanitin conjugates | FOLH1, ANPEP, PSMA6 | FOLH1 1/4885NAALAD2 157/4885RIMKLA 995/4885 |
| US-20250332296-A1 | ZWITTERIONIC METAL CHELATORS | SLC39A14, SLC7A1, SLC39A11 | FOLH1 66/4885NAALAD2 252/4885RIMKLA 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.